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Recent studies revealed the BRCA1 c.5339T>C, p.Leu1780Pro variant (L1780P) is highly
suggested as a likely pathogenic. The aim of this study was to evaluate clinicopathologic
features of L1780P with breast cancer (BC) using multicenter data from Korea to reinforce
the evidence as a pathogenic mutation and to compare L1780P and other BRCA1/2 muta-
tions using Korean Hereditary Breast Cancer (KOHBRA) study data.     
Materials and Methods
The data of 54 BC patients with L1780P variant from 10 institutions were collected and
the clinicopathologic characteristics of the patients were reviewed. The hereditary breast
and/or ovarian cancer–related characteristics of the L1780P variant were compared to
those of BC patients in the KOHBRA study. 
Results
The median age of all patients was 38 years, and 75.9% of cases showed triple-negative
breast cancer. Comparison of cases with L1780P to carriers from the KOHBRA study 
revealed that the L1780P patients group was more likely to have family history (FHx) of
ovarian cancer (OC) (24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p=0.001) and a personal
history of OC (16.7% vs. 2.9% vs. 1.3%, p=0.003 and p=0.001) without significant difference
in FHx of BC and bilateral BC. The cumulative risk of contralateral BC at 10 years after 
diagnosis was 31.9%, while the cumulative risk of OC at 50 years of age was 20.0%. Patients
with L1780P showed similar features with BRCA1 carriers and showed higher penetrance
of OC than patients with other BRCA1 mutations.   
Conclusion
L1780P should be considered as a pathogenic mutation. Risk-reducing salpingo-oophorec-
tomy is highly recommended for women with L1780P.
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Introduction
BRCA1 is a tumor suppressor gene, and its mutation is sig-
nificantly associated with hereditary breast cancer (BC) and
ovarian cancer (OC) (HBOC) syndrome [1,2]. A variant of
unknown significance (VUS) is a genetic variant that has
been identified by genetic testing but of which the functional
significance is not fully understood at this time [3]. Although
considerable effort has been put into reclassification of VUSs,
still, standardized guidelines have yet to be established.
The BRCA1 c.5339T>C, p.Leu1780Pro (L1780P) variant was
considered a VUS until previous studies revealed that it is
associated with HBOC syndrome [4-6]. Three studies from
Korea suggested that this variant showed highly suspected
features of a pathogenic BRCA1 mutation. However, all the
previous studies included fewer than 20 patients; thus, there
is a degree of uncertainty about the pathogenicity of the
L1780P mutation that has remained. Furthermore, interest-
ingly, reports of this variant are confined to the Korean pop-
ulation, and this variant has not been identified in Western
countries [7-10]. 
We evaluated the clinicopathologic features of the L1780P
variant in patients with BC using retrospective multicenter
data from Korea to verify L1780P as a pathogenic BRCA1
mutation. We also compared the characteristics related to
HBOC syndrome to identify HBOC-related characteristics




Twelve institutions initially agreed to participate in this
study. Ten of them subsequently provided data from pati-
ents with L1780P (S1A and S1B Fig.). Two institutions agreed
to participate in the study but could not identify patients
with the L1780P variant. One institute did not provide infor-
mation on the number of BRCA1/2 mutations. There was 
insufficient clinical information for five patients with L1780P.
Finally, a total of 64 patients with L1780P and BC and/or OC
from the 10 institutions was enrolled in this retrospective
study (Fig. 1). 
The clinicopathologic data and information were reviewed.
The clinicopathologic data included parity, marital status,
age at diagnosis, family history (FHx), and personal history
(PHx) of BC and/or OC, bilaterality of BC, pathologic stage
according to the seventh American Joint Committee on Can-
cer classification, estrogen receptor (ER), and progesterone
receptor (PR) status, human epidermal growth factor-2 (HER2)
status, nuclear grade, Ki-67 status, type(s) of operation,
type(s) of adjuvant treatment, risk-reducing procedures,
sampling date, genetic testing method(s), and tumor sub-
type(s). We compared the HBOC-related characteristics in
the patients with the L1780P variant to those of BC patients
from the Korean Hereditary Breast Cancer (KOHBRA) study.
Detailed information of enrolled patients in the KOHBRA
study has been previously described [11]. The clinical out-
comes were analyzed considering the following variables: 
recurrence, metachronous contralateral BC, and mortality.
Personal identifiers for all patients were removed prior to
analysis.
2. Diagnostic method
The BRCA1 L1780P variant was diagnosed using Sanger
sequencing (62 patients), next-generation sequencing (one
patient), conformation sensitive gel electrophoresis (one pati-
ent), and denaturing high-performance liquid chromatogra-
phy (one patient). Detailed information of the diagnostic




Patient characteristics were compared using independent
t test for continuous variables and chi-square or Fisher exact
test for categorical variables. Values are reported as mean±
standard deviation or median with range. Survival curves
were plotted using the Kaplan-Meier method. Recurrence-
free survival (RFS) rate was calculated from the date of dia-
gnosis or operation to the date of recurrence. Event-free
BRCA1/2 examined between 2006 and 2017.1,
12 institutions (n=2,804)a)
BCs (n=54)b) OCs (n=14)b) Unknown (n=5)
L1780P variant (n=64)
BRCA1/2 mutation (n=438)
Fig. 1. Schematic diagram of patient enrollment. BC,
breast cancer; OC, ovarian cancer. a)Two institutions have
no data of L1780P variant, b)Nine patients had breast and
ovarian cancer.
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survival (EFS) rate was calculated from the date of diagnosis
or operation to the date of any event related to BC and/or
OC. RFS was defined as any recurrence related to BC (e.g.,
local recurrence, distant metastasis, contralateral BC, and
death due to BC). EFS was defined as any recurrence 
related to BC and/or OC (local recurrence, distant metasta-
sis, contralateral BC, OC, and death by any cause). All tests
were two-sided. A p-value of < 0.05 was considered statisti-
cally significant. The SAS ver. 9.4 (SAS Institute Inc., Cary,
NC) and R3.2.1 (http://www.R-project.org; R Foundation for
Statistical Computing, Vienna, Austria) software packages
were used for statistical analyses.
4. Ethical statement
The World Medical Association Declaration of Helsinki on
medical research protocols and ethics was adhered to throug-
hout the procedures of this study. The Institutional Review
Board (IRB) reviewed and approved this study (IRB number
of National Cancer Center: 2017-04021, Kyungpook National
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ER, estrogen receptor; PR, progesterone receptor; HER2,
human epidermal growth factor-2; BCS, breast conserving
surgery; TM, total mastectomy; SLNB, sentinel lymph
node biopsy; ALND, axillary lymph node dissection. a)Ten
patients were staged after neoadjuvant chemotherapy,
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University Hospital: 2015-05-205, Samsung Medical Center:
2016-09-038, Seoul National University Hospital: 1702-063-
831, St. Mary's Hospital: KC19REDI0387, Yonsei University
Severance Hospital: 4-2016-1116). The need for informed con-
sent was waived because of the low risk posed by this inves-




A schematic diagram of patient selection is shown in Fig. 1.
Overall 2,804 BRCA1/2 mutation tests were performed in 
patients with BC and/or OC. Of those, 438 patients (15.6%)
had a BRCA1/2 mutation and 64 of 438 patients (14.6%) had
the L1780P variant. One thousand six hundred sixty-nine BC
patients in KOHBRA, 102 BRCA1 (6.1%), 143 BRCA2 (8.6%),
and two BRCA1/2 (0.1%) mutations were identified, while
1,442 patients (86.4%) did not show BRCA1/2 mutation. 
2. Patient characteristics
The clinicopathologic and treatment characteristics of the
54 BC patients with the L1780P variant are summarized in
Table 1. Only one patient (1.9%) showed a low histologic
grade while 41 patients (75.9%) demonstrated an intermedi-
ate to high nuclear grade. More than two-thirds of patients
showed ER and PR negativity (ER negativity: 42/54, 77.8%
and PR negativity: 45/54, 83.3%). HER2 overexpression was
present in only two patients (3.7%). Triple-negative breast
cancer was the most common subtype (41/54, 75.9%). 
3. Clinical features related to HBOC syndrome in the pati-
ent with L1780P compared with patients with BRCA1/2
mutation in KOHBRA
The characteristics related to HBOC syndrome in patients
L1780P and those with BRCA1/2 mutation in KOHBRA are
shown in Table 2. There was no significant difference in
mean age of BC or age group of BC (# 40 and > 40 year
groups) between cases with L1780P and those with BRCA1/2
mutation in KOHBRA (L1780P vs. BRCA1 vs. BRCA2, p >
0.999 and p=0.107, p=0.652 and p=0.144, respectively). Pati-
ents with L1780P were more likely to have FHx of BC or OC
(48/54, 88.9%) than patients with BRCA1/2 mutation in 
KOHBRA (75.3%, 186/241, p < 0.001). 
Patients with L1780P were more likely to have FHx of OC
(24.1%) and PHx of OC (16.7%) than those with BRCA1/2
mutation in KOHBRA (p < 0.001 and p=0.001, p=0.003 and
p=0.001, respectively). There was no significant difference in
FHx of BC, bilateral BC, or number of relatives with BC 
between L1780P and BRCA1/2 mutation groups, but the
L1780P variant group was more likely to have FHx of OC
(24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p < 0.001), and PHx
of OC (16.7% vs. 2.9% vs. 1.3%, p=0.009 and p < 0.001). In 
addition, the L1780P variant group had more number of rel-
atives with BC than BRCA1/2 mutation of KOHBRA (all, p <
0.001). There was no significant difference in the number of
relatives with OC between L1780P BRCA1/2 mutation of 
KOHBRA (p=0.351 and p=0.166, respectively). There was no
significant difference in the median age of OC onset (p=0.615
and p=0.800, respectively).
4. Clinical outcomes related to HBOC syndrome
RFS and EFS curves are shown in Fig. 2. The 5- and 10-year
RFS rates of patients with L1780P were 78.9% and 48.3%, res-
pectively (Fig. 2A), and the 5- and 10-year EFS rates of pati-
ents with L1780P were 52.4% and 28.8 (Fig. 2B). Thirteen BC
patients demonstrated bilateral breast cancer. The cumula-
tive risk of contralateral BC at 10 years after diagnosis was
31.9%, while the cumulative risk of OC at 50 years of age was
20.0% (Fig. 3A and B). 
Discussion
This study clearly demonstrated the clinicopathologic fea-
tures of patients with L1780P mutation using data collected
from 10 institutions in Korea and compared to other loca-
tions of BRCA1/2 mutation of KOHBRA. To our knowledge,
this study is the largest study of patients with L1780P vari-
ants and provides clear evidence that patients with L1780P
have similar clinicopathologic features to those of patients
with a pathogenic BRCA1 mutation. Patients with the L1780P
variant were more likely to have more frequent FHx and PHx
of OC than patients with other BRCA1/2 mutations in the
KOHBRA study.
Some pathogenic variants occur with high frequency 
because of a “founder effect” in particular racial/ethnic
groups. Several founder mutations have been identified in
specific populations, including Ashkenazi Jews [12-15]. The
three well-known founder mutations in the Ashkenazi Jew
population, BRCA1-185delAG, BRCA1-5382insC, and BRCA2-
6174delT pathogenic variants, account for about 90% of all
BRCA1/2 mutations in that population [16]. Interestingly, the
L1780P variant showed high frequency only in the Korean
population (Table 3). Previous research highlighted 33 pati-
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Age of BC (yr) 38.4±8.0 37.6±8.4 41.3±9.9 40.3±9.3 > 0.999 0.107 0.272
Age group (yr)
! 40 36 (66.7) 73 (71.6) 77 (53.8) 871 (61.3) > 0.999 0.432 > 0.999
< 40 18 (33.3) 29 (28.4) 66 (46.2) 551 (38.7)
No. of relatives with BC 1.6±0.7 1.0±0.9 0.9±0.9 0.5±0.7 < 0.001 < 0.001 < 0.001
Closet degree of relatives with BC
First-degree 27 (50.0) 45 (44.1) 59 (41.3) 359 (25.2) > 0.999 0.734 < 0.001
Second-degree 17 (31.5) 0 ( 1 (0.7) 2 (0.1) < 0.001 < 0.001 < 0.001
No. of relatives with BC
0 20 (37.0) 35 (34.3) 45 (31.5) 809 (56.9) > 0.999 0.321 < 0.001
1 18 (33.3) 41 (40.2) 74 (51.7) 525 (36.9)
2 11 (20.4) 19 (18.6) 18 (12.6) 74 (5.2)
! 3 4 (7.4) 7 (6.9) 6 (4.2) 14 (1.0)
Unknown 1 (1.9) 0 ( 0 ( 0 (
Bilateral BC 
(including metachronous BC)
Yes 13 (24.1) 14 (13.7) 38 (26.6) 170 (12.0) 0.482 > 0.999 0.044
No 41 (75.9) 88 (86.3) 105 (73.4) 1,252 (88.0)
Age of OC (yr) 49.2±11.2 45.0±11.3 46.3±16.6 51.5±15.9 0.615 0.800 0.754
Personal history of OC
Yes 9 (16.7) 3 (2.9) 2 (1.4) 6 (0.4) 0.009 < 0.001 < 0.001
No 43 (79.6) 99 (97.1) 141 (98.6) 1,416 (99.6)
Unknown 1 (1.9) 0 ( 0 ( 0 (
Family history of OCd)
Yes 13 (24.1) 20 (19.6) 16 (11.2) 64 (4.5) < 0.001 < 0.001 0.003
No 39 (72.2) 82 (80.4) 127 (88.8) 1,358 (95.5)
Unknown 2 (3.7) 0 ( 0 ( 0 (
No. of relatives with OC 0.57±1.72 0.20±0.40 0.11±0.32 0.05±0.21 0.351 0.166 0.084
No. of relatives with OC
0 41 (75.9) 82 (80.4) 127 (88.8) 1,358 (95.5) < 0.001 < 0.001 < 0.001
1 11 (20.4) 17 (16.7) 16 (11.2) 63 (4.4)
! 2 2 (3.7) 3 (2.9) 0 ( 1 (0.1)
Closet degree of relatives with OC NA NA NA
First-degree 12 (22.2) 12 (11.8) 8 (5.6) 38 (2.7) 0.290 0.002 < 0.001
Second-degree 3 (5.6) 7 (6.9) 7 (4.9) 17 (1.2) > 0.999 > 0.999 0.084
ER status
Negative 42 (77.8) 81 (79.4) 30 (21.0) 456 (32.1) 0.420 < 0.001 < 0.001
Positive 8 (14.8) 14 (13.7) 107 (74.8) 876 (61.6)
Unknown 4 (7.4) 7 (6.9) 6 (4.2) 90 (6.3)
PR status
Negative 45 (83.3) 75 (73.5) 51 (35.7) 487 (34.2) 0.035 < 0.001 < 0.001
Positive 5 (9.3) 20 (19.6) 85 (59.4) 842 (59.2)
Unknown 4 (7.4) 7 (6.9) 7 (4.9) 93 (6.5)
(Continued to the next page)
Table 2. Clinicopathologic features related to HBOC syndrome in breast cancer patients with L1780P and in the KOHBRA
study
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Negative 49 (90.7) 75 (73.5) 89 (62.2) 823 (57.9) 0.002 < 0.001 < 0.001
Overexpression 2 (3.7) 7 (6.9) 14 (9.8) 253 (17.8)
Equivocal 0 ( 8 (7.8) 29 (20.3) 208 (14.6)
Unknown 3 (5.6) 12 (11.8) 11 (7.7) 138 (9.7)
Male breast cancer 1 ( NA NA NA NA NA NA
Values are presented as mean±standard deviation or number (%). HBOC, hereditary breast and ovarian cancer; L1780P,
BRCA1 c.5339T>C (p.Leu1780Pro); KOHBRA, Korean Hereditary Breast Cancer; BC, breast cancer; OC, ovarian cancer; NA,
not available; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor-2. a)p-value for L1780P
vs. BRCA1, b)p-value for L1780P vs. BRCA2, c)p-value for L1780P vs. non-BRCA1/2, d)Seven patients had a family history of







































































































Fig. 3.  Cumulative contralateral breast cancer (A) and cumulative ovarian cancer (B) incidence in patients with BRCA1
c.5339T>C (p.Leu1780Pro).
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ents with L1780P variant, with the prevalence of the L1780P
variant of BC and OC being 26 of 2,147 (1.2%) and 11 of 436
(2.5%) and the proportions of the L1780P variant of BRCA1/2
and BRCA1 being 33 of 470 (7.0%) and 255 (12.9%), respec-
tively [4-6,17]. In this study, 64 of 458 patients with a BRCA1/2
mutation (12.8%) showed the L1780P variant. This suggests
that L1780P is a common mutation in Korean patients with
HBOC syndrome. In this study, among the seven patients
(13.5%) with family members with L1780P, the FHx of six 
patients (11.1%) showed co-segregation patterns of BC and/
or OC. The L1780P variant has been introduced as a likely
pathogenic variant in recent years; however, segregation
data from family members and haplotype analysis are not
available, and such investigations are necessary to confirm
whether L1780P is a founder mutation.
There are several reasons why a frequent and likely path-
ogenic variant (L1780P) had been classified as a VUS. One
reason for its classification as a VUS may be the rare preva-
lence in Western countries. There was only one carrier who
was of Asian ethnicity reported in the BIC database (http://
research.nhgri.nih.gov/bic/). Since the KOHBRA study was
started in 2007, the number of patients undergoing BRCA1/2
genetic testing has increased rapidly due to coverage of
BRCA1/2 genetic testing by the National Health Insurance
system of the South Korean government after May 2012 and
the onset of the “Angelina Jolie effect” in May 2013 [11,18,19].
However, reclassification of VUSs in the Korean population
is still not adequately performed due to limited data com-
pared with Western public databases such as BIC or ClinVar
(http://www.ncbi.nlm.nih.gov/clinvar/). VUSs continue to
be uncovered as BRCA1/2 pathogenic variants, especially in
developing countries. Of note, Korean clinicians asked Myrid
about the possibility of L1780P as a pathogenic variant and
categorized L1780P as a VUS according to previous func-
tional studies [20,21]. Several years later, they amended that
L1780P has been reclassified to a suspected deleterious muta-
tion based on a recent functional study and clinical report 
[4-6]. Even with many efforts to reduce VUSs, there is still a
possibility that more pathogenic variants are classified as
VUSs in the Korean population [22,23]. Thus, we should col-
lect more data using nationwide or global databases to 
reduce the rates of VUS designation. 
Rebbeck et al. [24] reported that BC and OC risks varied
by type and location of BRCA1/2 mutation, and that risk 
assessment and cancer prevention decision making for car-
riers should be approached based on the location of BRCA1/2
mutation. The author demonstrated three breast cancer clus-
ter regions (BCCRs) (c.179 to c.505, c.4328 to c.4945, and c.5261
to c.5563) and one ovarian cancer cluster region in BRCA1
mutation. Interestingly, L1780P is located in the BCCR but
showed more likely to have OC compare to data of KOH-
BRA. Recently, Park et al. [25] demonstrated that patients
with L1780P showed a relative risk of BC similar to that of
carriers with other known deleterious mutations located in
the BRCT domains of BRCA1. In addition, age at diagnosis
of BC in patients with L1780P (median, 38.4 years; 95% con-
fidence interval [CI], 33.9 to 42.9) was significantly earlier
than that of carriers with mutations outside of the putative
functional domain regions (median, 51.0 years; 95% CI, 45.0
to 57.0 years; p=0.017). In this study, the mean age at diag-
nosis of BC in patients with L1780P showed no significant
difference compared with that of patients with BRCA1 muta-
tion in KOHBRA. Further investigations are needed to vali-
date the location of BRCA1/2 mutation and the risk of cancer
prevalence in Korea as well as the other parts of the world,
especially in northeastern Asian countries. 
There are some limitations in the present study, including
its retrospective design and loss of data collection. However,
a prospective cohort study on this topic may be nearly 
impossible and is not a suitable design for research on rare
mutations in a specific population. Furthermore, to the best
of our knowledge, the current study presents the largest
number of patients with the L1780P variants to date and
demonstrates clear clinicopathologic evidence that the L1780P
Table 3.  Previous studies reporting frequency of the BRCA1 c.5339T>C (p.L1780P) variant
Values are presented as number (%). NA, not available; NCC, National Cancer Center; SMC, Samsung Medical Center; YCC,
Yonsei Cancer Center. a)One patient was male breast cancer, b)Two patients had breast cancer and ovarian cancer, c)Three 
patients had breast cancer and ovarian cancer, d)Nine patients had breast and ovarian cancer.
No. of L1780P Total No. of Total No. of Proportion of Proportion of Referencevariants breast cancers ovarian cancers BRCA1/2 mutation BRCA1 mutation
4 4/328 NA 4/49 (10.3) 4/21 (19.0) NCC
16 12/1,223a) 6/174 (3.2)b) 16/244 (6.6) 16/139 (11.5) SMC
11 10/596c) 3/124 (2.4)c) 11/144 (7.6) 11/69 (15.9) YCC
2 NA 2/138 (2.2) 2/33 (6.1) 2/26 (7.7) CHA
64 54d) 14d) 64/458 (12.8) NA Current study
Cancer Res Treat. 2020;52(3):680-688
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variant is a pathogenic variant of BRCA1. 
In conclusion, patients with L1780P variant showed similar
clinicopathologic features to patients with BRCA1 pathogenic
mutation, so that L1780P variant in BRCA1 should be con-
sidered as pathogenic BRCA1 mutation. RRSO should be
highly recommended for women with the L1780P variant.
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